{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:42Z","timestamp":1791105702263,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"M.J. Fox Foundation Clinical Intervention Award 2008"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.parkreldis.2012.12.003","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T00:15:56Z","timestamp":1356912956000},"page":"416-421","source":"Crossref","is-referenced-by-count":28,"title":["Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (\u201cn-of-1\u201d) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients"],"prefix":"10.1016","volume":"19","author":[{"given":"Fran\u00e7ois","family":"Tison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"N\u00e8gre-Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dupouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Thiollier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Galitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory-Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Milhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Marquine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2012.12.003_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurol"},{"issue":"3","key":"10.1016\/j.parkreldis.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.mp.4001291","article-title":"Targeting Ras\/ERK signaling in the striatum: will it help?","volume":"8","author":"Brambilla","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coph.2006.08.012","article-title":"ERK2: a logical AND gate critical for drug-induced plasticity?","volume":"7","author":"Girault","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1073\/pnas.1012071107","article-title":"Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia","volume":"14","author":"Fasano","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","article-title":"Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia","volume":"5","author":"Santini","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1523\/JNEUROSCI.4720-07.2008","article-title":"The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease","volume":"28","author":"Schuster","year":"2008","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","article-title":"The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1","volume":"15","author":"Li","year":"2005","journal-title":"Curr Biol"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/bdd.347","article-title":"Pharmacokinetics and bioequivalence evaluation of two simvastatin 40\u00a0mg tablets (Simvast and Zocor) in healthy human volunteers","volume":"24","author":"Najib","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib15","first-page":"301","article-title":"Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS\/MS without polarity switch: application to a bioequivalence study","volume":"31","author":"Patel","year":"2008","journal-title":"J\u00a0Sep Sci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1472-8206.2011.00951.x","article-title":"A\u00a0proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease","volume":"26","author":"Rascol","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","article-title":"RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease","volume":"27","author":"Gold","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","article-title":"Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning","volume":"22","author":"Guigoni","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A\u00a0critique of available scales and presentation of the non-human primate dyskinesia rating scale","volume":"15","author":"Fox","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0197-2456(90)90003-K","article-title":"N\u00a0of 1 randomized trials for investigating new drugs","volume":"11","author":"Guyatt","year":"1990","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1073858410385006","article-title":"Prospects of statins in Parkinson disease","volume":"17","author":"Roy","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","article-title":"Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences","volume":"32","author":"Lennernas","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-5728(01)00317-4","article-title":"Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes","volume":"117","author":"Amenta","year":"2001","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W","article-title":"Increased expression of dopamine receptors on lymphocytes in Parkinson's disease","volume":"14","author":"Barbanti","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jneumeth.2008.07.018","article-title":"Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays","volume":"174","author":"Kirillova","year":"2008","journal-title":"J\u00a0Neurosci Methods"},{"key":"10.1016\/j.parkreldis.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1097\/00001756-199909290-00006","article-title":"Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease","volume":"10","author":"Caronti","year":"1999","journal-title":"Neuroreport"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012004804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012004804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T14:33:11Z","timestamp":1562509991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802012004804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1353802012004804"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2012.12.003","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}